Aerovate Therapeutics, Inc.
NASDAQ Global MarketCapital Structure
•
in mil. unless spec.Working Capital
•
in mil. unless spec.Growth Rates
•
in mil. unless spec.Quarterly Revenue
•
in mil. unless spec.Quarterly Earnings Per Share
•
in mil. unless spec.Quarterly Dividends Per Share
•
in mil. unless spec.- CEO
- Timothy P. Noyes
- Full Time Employees
- 4
- Sector
- Healthcare
- Industry
- Biotechnology
- Address
- 930 Winter Street Waltham MA United States of America 02116
- IPO Date
- Jun 30, 2021
- CIK
- 0001798749
- Website
- aerovatetx.com
- Similar Companies
- Business
- Aerovate Therapeutics, Inc. (AVTE) is a clinical-stage biopharmaceutical company focused on developing innovative therapies for rare cardiopulmonary diseases, including pulmonary arterial hypertension (PAH). The company offers AV-101, a proprietary dry powder inhaled formulation of imatinib designed for targeted delivery to diseased lung tissues to inhibit cellular proliferation in narrowed pulmonary arteries, potentially improving efficacy and reducing systemic exposure compared to oral forms; it targets patients with PAH, a progressive condition affecting the heart and lungs, where existing vasodilator therapies provide symptomatic relief but fail to address underlying disease drivers. Aerovate operates primarily in the United States, with headquarters in Waltham, Massachusetts, and was founded in 2018. In a major strategic shift, Aerovate completed a merger with Jade Biosciences in April 2025, creating a combined entity advancing Jade's autoimmune disease pipeline, including lead candidate JADE-101 (formerly JADE-001), an antibody inhibiting the APRIL protein for immunoglobulin A nephropathy (IgAN) to reduce pathogenic IgA levels, proteinuria, and kidney damage, alongside preclinical programs JADE-002 and JADE-003; the transaction included an oversubscribed $300 million private placement financing from investors such as Fairmount, Venrock Healthcare Capital Partners, RA Capital Management, and OrbiMed, expected to fund operations through 2027, and Aerovate declared a special cash dividend of approximately $69.6 million ($2.40 per share) to stockholders ahead of the closing. The merged company, operating under Jade Biosciences branding, expands into autoimmune therapies while retaining focus on cardiopulmonary innovation, with redirected resources from AV-101 supporting Jade's clinical-stage assets licensed from Paragon Therapeutics; it maintains a presence in North America, headquartered post-merger with operations linked to Vancouver, British Columbia, and San Francisco.
Aerovate Therapeutics (NASDAQ:AVTE) & AEON Biopharma (NASDAQ:AEON) Head to Head Survey
Aerovate Therapeutics (NASDAQ:AVTE) Trading Down 0.5% – Here’s Why
Reviewing Aerovate Therapeutics (NASDAQ:AVTE) & Graybug Vision (NASDAQ:GRAY)
19,564 Shares in Aerovate Therapeutics, Inc. (NASDAQ:AVTE) Purchased by Squarepoint Ops LLC
Jade Biosciences Completes Closing of Merger with Aerovate Therapeutics and Previously Announced Private Placement of Approximately $300 Million
Aerovate Therapeutics Stockholders Approve Proposed Merger with Jade Biosciences and All Related Proposals
Aerovate Therapeutics Declares Special Cash Dividend in Connection with the Proposed Merger with Jade Biosciences
Aerovate Therapeutics Announces Range of Expected Cash Dividend in Connection with the Proposed Merger with Jade Biosciences
AEROVATE THERAPEUTICS INVESTOR ALERT by the Former Attorney General of Louisiana: Kahn Swick & Foti, LLC Investigates Merger of Aerovate Therapeutics, Inc. - AVTE
AVTE Stock Alert: Halper Sadeh LLC Is Investigating Whether the Merger of Aerovate Therapeutics, Inc. Is Fair to Shareholders
INVESTOR ALERT: The M&A Class Action Firm Investigates the Merger of Aerovate Therapeutics, Inc. – AVTE
INVESTOR ALERT: The M&A Class Action Firm Investigates the Merger of Aerovate Therapeutics, Inc. - AVTE
SHAREHOLDER INVESTIGATION: Halper Sadeh LLC Investigates AVTE and PFIE on Behalf of Shareholders
AVTE Stock Alert: Halper Sadeh LLC Is Investigating Whether the Merger of Aerovate Therapeutics, Inc. Is Fair to Shareholders
Shareholder Alert: Ademi LLP Investigates Whether Aerovate Therapeutics, Inc. Is Obtaining a Fair Price for Its Public Shareholders
Aerovate Therapeutics to Explore Strategic Alternatives
The 3 Hottest Stock Downgrades From Last Week
Investigation Into Aerovate Therapeutics, Inc. (AVTE) Announced byHolzer & Holzer, LLC
Aerovate Therapeutics Investors: Investigation on behalf of investors; the Portnoy Law Firm
Aerovate (AVTE) Down as Lead Drug Fails to Meet PAH Study Goals